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Purpose: Based on the previous indications of founder ATP-binding cassette sub-family A member 4 gene (ABCA4)
mutations in a South African subpopulation, the purpose was to devise a mechanism for identifying common disease-
causing mutations in subjects with ABCA4-associated retinopathies (AARs). Facilitating patient access to this data and
determining the frequencies of the mutations in the South African population would enhance the current molecular
diagnostic service offered.
Methods: The majority of subjects in this study were of Caucasian ancestry and affected with Stargardt macular dystrophy.
The initial cohort consisted of DNA samples from 181 patients, and was screened using the ABCR400 chip. An assay
was then designed to screen a secondary cohort of 72 patients for seven of the most commonly occurring ABCA4 mutations
in this population. A total of 269 control individuals were also screened for the seven ABCA4 mutations.
Results: Microarray screening results from a cohort of 181 patients affected with AARs revealed that seven ABCA4
mutations  (p.Arg152*,  c.768G>T,  p.Arg602Trp,  p.Gly863Ala,  p.Cys1490Tyr,  c.5461–10T>C,  and  p.Leu2027Phe)
occurred at a relatively high frequency. The newly designed genetic assay identified two of the seven disease-associated
mutations in 28/72 patients in a secondary patient cohort. In the control cohort, 12/269 individuals were found to be
heterozygotes, resulting in an estimated background frequency of these mutations in this particular population of 4.46 per
100 individuals.
Conclusions: The relatively high detection rate of seven ABCA4 mutations in the primary patient cohort led to the design
and subsequent utility of a multiplex assay. This assay can be used as a viable screening tool and to reduce costs and
laboratory time. The estimated background frequency of the seven ABCA4 mutations, together with the improved
diagnostic service, could be used by counselors to facilitate clinical and genetic management of South African families
with AARs.
Stargardt disease (STGD; OMIM 248200) is a juvenile-
onset form of macular dystrophy (MD) characterized by loss
of photoreceptor cells in the macula, resulting in a severe
reduction of central vision [1]. The macula is situated in the
central region of the retina and contains a high concentration
of cone photoreceptor cells [2]. STGD, which can have either
an autosomal recessive or an autosomal dominant mode of
inheritance [3], is one of the most frequent causes of MD in
childhood, accounting for approximately 7% of all retinal
degenerative  diseases  (RDDs)  [4],  with  an  estimated
incidence of 1 in 10,000 individuals [5].
Clinical  features  of  the  disease  include  progressive
bilateral degeneration of the macula and the retinal pigment
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epithelium. The appearance of orange-yellow flecks located
around the macula or the mid-retinal periphery is a distinctive
feature of STGD [1]. Fluorescein angiography has shown the
choroid  to  be  dark  in  many  patients,  which  indicates  the
accumulation  of  lipofuscin.  Lipofuscin  consists  of  a
combination of different fluorescent by-products of the visual
cycle and appears to have toxic effects on the retinal pigment
epithelium [6].
To date, the ATP (ATP)-binding cassette, subfamily A
(ABC1), member 4 gene, ABCA4, which codes for the retina-
specific ATP-binding cassette transporter, is the only gene
known  to  be  involved  with  autosomal  recessive  STGD
(arSTGD) [1].
The ABCA4 protein is expressed in the outer segment of
the rod and cone photoreceptor cells in the retina [5,7]. Protein
misfolding, decreased functioning, and mislocalization due to
ABCA4  mutations  have  been  described  for  ABCA4-
associated retinopathies (AARs). Mutations in ABCA4 have
been found to be associated not only with arSTGD but also
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280with  other  clinical  forms  of  RDDs,  including  fundus
flavimaculatus, cone-rod dystrophy, and autosomal recessive
retinitis pigmentosa [1]. More than 500 mutations have been
identified  in  ABCA4,  including  single-base  substitutions,
duplications, and deletions [8].
Previous research performed in the Division of Human
Genetics  at  the  University  of  Cape  Town,  South  Africa
identified possible ABCA4 founder mutations, occurring at a
relatively  high  frequency  in  the  South  African  Caucasian
population, specifically those of Afrikaner descent [9]. With
the  development  of  the  ABCR400  microarray  [10],  an
effective,  rapid  screening  tool  became  available  for  the
genetic confirmation of diagnosis of AARs. We previously
evaluated the utility of the ABCR400 microarray and stressed
the  importance  of  validating  the  chip  data  by  verifying
mutations  and  familial  investigations,  before  delivering
results to patients [11]. Additional samples have subsequently
been screened, and the validated chip data, including mutation
spectrum  and  mutation  frequencies,  are  reported  here.
Importantly, based on the frequencies of mutations identified
in South African patients with STGD, it may be possible to
target testing and provide a cost-effective diagnostic service.
METHODS
RDD patients and their family members were referred to the
Division of Human Genetics from throughout South Africa,
by ophthalmologists and the lay support society, Retina South
Africa. Individuals were invited to participate in the RDD
research program, and informed consent was obtained from
patients according to the tenets of the Declaration of Helsinki
(2008). The consent forms and patient information sheets used
in the RDD project had previously been approved by the
University of Cape Town Research Ethics Committee (FHS
HREC  REF  226/2010).  Biologic  material,  demographic
information,  relevant  clinical  details  and  diagnoses  were
archived  for  each  patient,  together  with  information  as
supplied, relating to additional health issues.
ABCR400 microarray screening: A total of 181 samples
from affected probands with AARs were screened using the
ABCR400 chip (Asper Ophthalmics, Tartu, Estonia). This
includes the 132 samples previously described [11] and an
additional 49 samples. The ethnic categorization of the patient
cohort was as follows: 152 Caucasians, 17 indigenous Black
Africans,  seven  Indians,  and  five  individuals  of  mixed
ancestry. Most (n=133) of the patients had a diagnosis of
arSTGD,  while  the  remainder  were  diagnosed  with  MD
(n=19) or isolated cases of RP (n=24), or were probands from
families  diagnosed  with  autosomal  recessive  retinitis
pigmentosa (n=5). All results obtained from the ABCR400
microarray screening were verified, and familial mutation
cosegregation analysis was performed wherever possible, as
previously described [11]. Briefly, PCR was performed to
amplify the exons harbouring each mutation detected using
the microarray. Probands were tested using restriction enzyme
digests  or  direct  sequencing  (ABI  Prism  3100  automated
sequencer; Applied Biosystems, Foster City, CA) to verify the
presence  of  each  mutation.  Cosegregation  studies  were
performed to test for the presence of each mutation in samples
from  family  members,  using  restriction  enzyme  digests,
denaturing  high-performance  liquid  chromatography
(dHPLC)  analysis  (WAVE®  Nucleic  Acid  Fragment
Analysis System; Transgenomic Inc., Omaha, NE), allele-
specific  PCR  (AS-PCR),  or  direct  sequencing.  Proband
samples were included in the co-segregation analysis, having
been amplified in a separate reaction to the initial verification
experiment.
Detection  of  seven  ABCA4  mutations:  A  locally-
developed  diagnostic  assay  was  established  to  interrogate
seven common ABCA4 mutations in a cohort of samples from
72 unrelated patients who had not previously been screened
using the ABCR400 microarray. Most of the patients (n=70)
were  affected  with  STGD,  while  the  remainder  had  a
diagnosis of cone-rod dystrophy (n=2). The ethnic breakdown
of the patient cohorts was as follows: 60 were Caucasian, eight
individuals were of mixed ancestry, three were Indian, and
one was of indigenous Black African origin.
In addition, the assay was used to screen a cohort of 269
Caucasian control individuals, 169 of whom were specifically
of  Afrikaner  descent.  Individuals  were  defined  as  being
Afrikaner based on their family name and stated ancestry upon
recruitment. Furthermore, for 119 of these 169 individuals,
pedigrees indicated that this sub-cohort had been in South
Africa for two or more generations. The pedigrees verified
Afrikaner descent, showing the individuals to be of European
origin,  with  distinct  input  from  the  Dutch,  German,  and
French  population  groups.  This  control  cohort  comprised
individuals who had not been previously assessed for the
presence of an RDD.
Seven exons (exons 5, 6, 13, 17, 30, 39, and 44) of the
ABCA4 gene were amplified using PCR (Table 1). The PCR
products  were  screened  for  the  seven  common  ABCA4
mutations with a multiplex assay intended to streamline our
former  approach  to  mutation  validation  [11].  Four  of  the
mutations were detected with SNaPshot PCR (p.Cys1490Tyr,
p.Arg602Trp, c.5461–10T>C, and p.Leu2027Phe mutations;
Table  2,  Figure  1,  Figure  2,  and  Figure  3)  using  the
SNaPshot®  Multiplex  Ready  Reaction  Mix  (Applied
Biosystems,  Warrington,  UK),  resolved  on  the  ABI  3100
Genetic  Analyzer  (Applied  Biosystems)  and  subsequently
analyzed  using  the  GeneMapper  3.0  GeneScan  software
(Applied  Biosystems).  The  p.Arg152*  (Figure  4)  and  c.
768G>T (Figure 5) mutations were screened for with dHPLC
analysis using the WAVE® Nucleic Acid Fragment Analysis
System (Transgenomic Inc.). AS-PCR was used to screen for
the p.Gly863Ala mutation (Table 3), and the PCR products
were separated using non-denaturing dHPLC conditions on
the WAVE® System (Figure 6). Direct cycle sequencing was
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281performed  using  the  BigDye  Terminator  v3.1  Cycle
Sequencing Kit (Applied Biosystems, Foster City, CA) on
samples shown to have dHPLC profile alterations (Figure 5).
These  samples  were  resolved  on  the  ABI  3100  Genetic
Analyzer  (Applied  Biosystems).  Family  studies  were
performed wherever possible (depending on the availability
of samples) for probands found to carry at least two mutations.
RESULTS
ABCR400  microarray  screening:  Of  the  181  samples
screened  using  the  ABCR400  microarray,  a  total  of  99
(54.69%) were characterized completely, i.e., to the point of
identifying  at  least  two  disease-causing  mutations
(specifically, nine were homozygotes and 90 were presumed
to be compound heterozygotes, although only 41 could be
verified as having biallelic mutations through family studies).
TABLE 1. INFORMATION PERTAINING TO THE PRIMERS USED TO AMPLIFY THE EXONS CONTAINING THE SEVEN MOST COMMON ABCA4 MUTATIONS.
Exon (mutation) Primer 5′-3′ Annealing
temperature
Mutation detection technique
Exon 5 (p.Arg152*) F: gacccatttccccttcaac 60 °C dHPLC, Cycle sequencing using the reverse primer
  R: aggctgggtgcttccctc    
Exon 6 (c.768G>T) F: ggtgtctttcctaccacag 57.9 °C dHPLC, Cycle sequencing using the forward primer
  R: aggaatcaccttgcaattgg    
Exon 13 (p.Arg602Trp) F: agctatccaagcccgttcc 63 °C SNaPshot PCR
  R: ccattagcgtgtcatggag    
Exon 17 (p.Gly863Ala) F: ctgcggtaaggtaggataggg 60 °C Allele-specific PCR
  R: cacaccgtttacatagagggc    
Exon 30 (p.Cys1490Tyr) F: gtcagcaactttgaggctg 63 °C SNaPshot PCR
  R: tccctctgtggcaggcag    
Intron38/Exon39 (c.5461–10T>C) F: gccccacctgctgaagag 63 °C SNaPshot PCR
  R: tcccagctttggacccag    
Exon 44 (p.Leu2027Phe) F: gaagcttctccagccctagc 63 °C SNaPshot PCR
  R: tgcactctcatgaaacaggc    
TABLE 2. INFORMATION PERTAINING TO THE PRIMERS DESIGNED FOR THE SNAPSHOT MULTIPLEX REACTION.
Exon (mutation) Primer length (bp)
with tail
Primer sequence (with tail, 5′-3′)*
13 (p.Arg602Trp) 34 R: tgttccagtgccacgaacccgccccagatgtacc
30 (p.Cys1490Tyr) 32 R: cttcgtggttactgagcttctccctggtgctg
39 (Intron 38) (c.5461–10T>C) 37 F: ccgatgtagttgaccccgtttccaacagtcctacttc
44 (p.Leu2027Phe) 41 R: tactctggatcttagtaggtaaagatgttctcgtcctgtga
           *The nucleotide sequence in bold is the sequence designed to bind complementary to the genomic DNA sequence. The nucleotide
          sequence not written in bold is the random nucleotide tail added to the primer sequence.
Figure 1. An electropherogram of the
multiplex SNaPshot reaction shows the
results  obtained  for  a  sample  that  is
heterozygous for the p.Arg602Trp and
p.Cys1490Tyr  mutations.  The
p.Arg602Trp  alleles  are  indicated  by
blue and green peaks at 36 bp and 37 bp,
respectively. The p.Cys1490Tyr alleles
are indicated by black and red peaks at
38 bp and 39 bp, respectively. The c.
5461–10 wild-type allele is represented
by a red peak at 41.5 bp. The p.Leu2027
wild-type allele is represented by a blue
peak at 45 bp. The LIZ Size Standard
can be seen at 35 bp.
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282The  remainder  of  the  samples  were  either  partially
characterized, i.e., with either a single, heterozygous mutation
(n=49;  27.07%)  or  no  mutation  (n=33;  18.23%).  The
identification of causative mutations in approximately 55% of
the cohort in the current study is comparable to our initial
findings, where 60% of the cohort was characterized [11].
A total of 51 distinct ABCA4 mutations were identified.
However,  seven  mutations  (p.Arg152*,  c.768G>T,
p.Arg602Trp, p.Gly863Ala, p.Cys1490Tyr, c.5461–10T>C,
and  p.Leu2027Phe)  occurred  at  a  significantly  higher
frequency, compared to the other variants in the cohort (Table
4).
Of the 99 completely characterized subjects (i.e., both
disease-causing  mutations  identified),  64  showed  two
mutated alleles from this prevalent set of seven mutations
(n=128 alleles), while 23 had a single allele from this high-
incidence subset (n=23).
Of the 49 partially characterized samples (i.e., where only
one disease-causing mutation was identified), 28 had one of
the prevalent mutations (n=28). In total, 179 of the 362 alleles
(49.45%) represented the seven common mutations.
Based on the mutation frequencies observed, one would
expect approximately 35.2% (0.65×0.55) of samples from
South African Caucasian STGD patients to be potentially
fully characterized by screening for only the seven mutations.
Detection  of  seven  ABCA4  mutations:  A  total  of  78/144
(54.17%)  disease-causing  mutations  were  detected  in  the
secondary cohort of 72 patients screened (Table 5). Twenty-
eight patients (38.89%) were found to carry two mutations.
The majority of the patients found to carry two mutations were
presumed to be compound heterozygotes (n=23 individuals,
82.14%), with the remaining five homozygotes (17.86%). In
these  28  individuals,  ABCA4  is  thus  presumed  to  be  the
disease-causing gene, although family studies to prove the
mutations were biallelic could be performed for only seven
compound  heterozygous  individuals.  Twenty-two  patients
(30.55%) were found to carry one ABCA4 mutation, meaning
that another rarer ABCA4 mutation may exist or that a different
gene causes the condition. Finally, 22 patients (30.55%) were
shown not to carry any of the seven mutations, indicating that
either two rarer ABCA4 mutations exist or that a different gene
could cause the condition.
Of the 269 control samples screened, 12 (4.46%) were
shown  to  carry  a  heterozygous  mutation  (Table  5).  Four
heterozygotes  (4%)  were  detected  in  the  Caucasian  sub-
cohort,  with  eight  heterozygotes  (4.73%)  detected  in  the
Afrikaner sub-cohort.
DISCUSSION
Through ABCR400 microarray analysis of 181 AAR samples,
seven specific mutations accounted for approximately 50% of
the disease-causing alleles.
The  seven  common  mutations  were  all  regarded  as
pathogenic contributors to disease. Functional analysis of the
p.Arg602Trp and p.Cys1490Tyr mutations showed that these
missense alleles result in misfolding and mislocalization of
the ABCA4 protein, as well as a marked reduction in ATPase
activity [12]. The c.768G>T mutation, although isocoding
(Val256Val), has been shown to affect splicing and results in
a lack of the mRNA transcript [13]. The same study showed
that  the  p.Gly863Ala  mutation,  which  occurs  in  the  first
nucleotide and hence the splice acceptor site of exon 17,
Figure 2. An electropherogram of the
multiplex  SNaPshot  reaction  showing
the results obtained for a sample that is
heterozygous  for  the  p.Leu2027Phe
mutation. The p.Arg602 wild-type allele
is indicated by a blue peak at 36 bp. The
p.Cys1490 wild-type allele is indicated
by a black peak at 38 bp. The c.5461–10
wild-type allele is represented by a red
peak  at  41.5  bp.  The  p.Leu2027Phe
alleles are represented by blue and green
peaks at 45 bp and 46 bp, respectively.
The LIZ Size Standard can be seen at 35
bp.
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283results in a mixture of mutant ABCA4 proteins. The presence
of  this  mutation  has  been  reported  to  reduce  the  splice
potential at the normal splice site, and increase the splice score
at a cryptic site three base pairs downstream [13]. The encoded
protein therefore either lacks the p.Gly863 amino acid (due to
cryptic splicing) or carries the missense mutation [13,14]. The
p.Arg152* mutation leads to a premature stop codon in exon
5,  thereby  causing  inactivation  of  the  ABCA4  allele  [3].
Functional analysis of the Nucleotide Binding Domain 2 of
ABCA4,  which  contains  the  p.Leu2027Phe  mutation,  has
indicated that mutations in this domain cause inhibition of
ATP hydrolysis [14]. Although the c.5461–10T>C mutation
has been shown not to cause aberrant splicing of exon 39
[15], the mutation may affect splicing of another exon or may
affect  the  protein  in  another  way.  Several  studies  have
reported this rare sequence variant as being likely to cause
retinal disease or existing in linkage disequilibrium with a
pathogenic  mutation  [13,15,16].  Furthermore,  two  recent
studies investigating the pathogenic contributions of ABCA4
mutations  reported  the  c.5461–10T>C  mutation  to  be  a
relatively severe allele [17,18].
A  study  has  shown  that  there  were  several  possible
ABCA4  founder  mutations,  occurring  at  a  relatively  high
frequency in the South African Caucasian population [9].
More than 90% of the South African cohort interrogated by
September et al. [9] was of Afrikaner descent, and 84% of the
Figure 3. An electropherogram of the
multiplex  SNaPshot  reaction  showing
the results obtained for a sample that is
heterozygous  for  the  c.5461–10T>C
mutation. The p.Arg602 wild-type allele
is indicated by a blue peak at 36 bp. The
p.Cys1490 wild-type allele is indicated
by a black peak at 38 bp. The c.5461–
10T>C alleles are represented by a black
and  red  peak  at  40  bp  and  41.5  bp,
respectively. The p.Leu2027 wild-type
allele is represented by a blue peak at 45
bp. The LIZ Size Standard can be seen
at 35 bp.
Figure 4. A chromatogram, generated
using  denaturing  high-performance
liquid chromatography, shows the wild
type  profile,  and  the  profile  obtained
when  a  heterozygous  p.Arg152*
mutation is present.
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284microarray  cohort  in  the  present  study  was  of  Caucasian
ancestry. The Caucasian population in South Africa originated
from  the  immigration  of  settlers  from  Europe,  with  the
Afrikaner  population  originating  from  individuals  from
Holland,  Germany,  and  France  [19].  Afrikaners  form  a
distinct,  biologically  homogeneous  group,  and  several
inherited  diseases  have  been  described  due  to  founder
mutations [20]. A locally developed assay that allows targeted
screening  of  the  seven  common  mutations  in  Caucasians
(particularly  those  of  Afrikaner  descent)  with  STGD  was
developed to aid in diagnostic and predictive testing offered
to families with AARs. To further improve the clinical utility
of this diagnostic assay, a control cohort was screened to
determine  the  carrier  frequencies  of  the  mutations  in  this
population, thereby providing valuable risk information for
genetic counseling.
Patient cohort screening: In a screening of 72 unrelated
patients  affected  with  AARs,  at  least  one  of  the  seven
ABCA4 mutations was detected in 50 (69.44%) patients; this
included 28 (38.89%) individuals in whom two mutations
were identified (i.e., these individuals are presumed to be
completely  characterized,  although  it  was  not  possible  to
prove the mutations were biallelic in all cases).
The p.Cys1490Tyr mutation was found to be the most
frequently occurring mutation, detected in 19.44% of patient
samples. This mutation was also found to be most commonly
occurring in the September et al. study [9], as well as in the
ABCR400 microarray analysis (Table 4), where the majority
of the patients were affected with STGD. This mutation is
therefore  the  most  common  in  the  South  African  STGD
cohort.
Figure  5.  Sequencing
electropherograms  show  (A)  the
heterozygous c.768G>T mutation, (B)
homozygous c.768G>T mutation, and
(C)  the  wild-type  sequence  following
denaturing  high-performance  liquid
chromatography screening.
TABLE 3. INFORMATION PERTAINING TO THE PRIMERS DESIGNED FOR AS-PCR FOR GLY863ALA MUTATION DETECTION.
Exon (mutation) Primer name (bp) Primer length Primer sequence* (5′-3′)
17 Gly863Ala-Rc 26 tttttgaagtggggttccatagtcag
  Gly863Ala-Rg 36 gcgtgcttggggtatgaagtggggttccatagtcac
          Gly863Ala-Rc: The AS-PCR primer designed specifically to bind to the nucleotide, cytosine (C), when exon 17 does not contain
          the p.Gly863Ala mutation, and is therefore known as the wild type primer. Gly863Ala-Rg: The AS-PCR primer designed
          specifically to bind to the nucleotide, guanine (G), when exon 17 contains the p.Gly863Ala mutation, and is therefore known
          as the mutation-specific primer. *The nucleotide sequence in bold is the sequence designed to bind complementary to the
          genomic DNA sequence. The nucleotide sequence not written in bold is the random nucleotide tail added to the primer sequence.
Figure 6. A chromatogram, generated
using  denaturing  high-performance
liquid chromatography following allele-
specific  PCR,  shows  the  wild  type
profile and the profile obtained when a
heterozygous p.Gly863Ala mutation is
present.
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285Of  the  seven  ABCA4  mutations,  p.Arg152*  and
p.Gly863Ala occurred least frequently; each was detected in
seven (9.72%) patient samples. These mutations were also
found to be the least commonly detected in the September et
al. study [9], as well as in the results obtained from microarray
analysis  using  the  ABCR400  chip  screening.  These  two
mutations  are  therefore  the  least  commonly  occurring
mutations in the South African STGD cohort.
As discussed by September et al. [9], the majority of the
common mutations have been found to occur at a higher
frequency  in  the  South  African  population  compared  to
populations  in  Europe  [15,21].  With  the  exception  of  the
TABLE 4. SPECTRUM OF ABCA4 MUTATIONS DETECTED USING THE ABCR400 MICROARRAY IN 181 SOUTH AFRICAN PROBANDS
Amino acid change Nucleotide change No. of alleles detected Frequency
p.Cys54Tyr c. 161 G>A 2 0.55%
p.Arg152* c. 454 C>T 12 3.31%
p.Arg152Gln c. 455 G>A 3 0.83%
p.Gly172Ser c. 514 G>A 1 0.28%
p.Arg212Cys c. 634 C>T 1 0.28%
p.Lys223Gln c. 667 A>C 1 0.28%
p.V256V (Splice) c. 768 G>T 18 4.97%
p.Pro291Leu c. 872 C>T 1 0.28%
p.Trp439* c. 1317 G>A 1 0.28%
p.Ala538Asp c. 1613 C>A 1 0.28%
p.Leu541Pro c. 1622 T>C 1 0.28%
p.Arg602Trp c. 1804C>T 30 8.29%
p.Val643Met c. 1927 G>A 1 0.28%
p.Arg653Cys c. 1957 C>T 1 0.28%
p.Arg681* c. 2041 C>T 3 0.83%
p.Val767Asp c. 2300 T>A 1 0.28%
p.Trp855* c.2564_2571delGGTACCTT 2 0.55%
p.Gly863Ala c. 2588 G>C 11 3.04%
p.Val931Met c. 2791 G>A 1 0.28%
p.Asn965Ser c. 2894 A>G 4 1.10%
p.Val989Ala c. 2966 T>C 1 0.28%
p.Gly991Arg c. 2971 G>C 1 0.28%
p.Thr1019Met c. 3056 C>T 1 0.28%
p.Ala1038Val c. 3113 C>T 3 0.83%
p.Glu1087Lys c. 3259 G>A 1 0.28%
p.Arg1108Cys c. 3322 C>T 2 0.55%
p.Leu1201Arg c. 3602 T>G 4 1.10%
p.Arg1300Gln c. 3899 G>A 4 1.10%
p.Pro1380Leu c. 4139 C>T 3 0.83%
p.Trp1408Arg c. 4222 T>C 1 0.28%
- c. 4253+5G>A 1 0.28%
p.Phe1440Ser c. 4319 T>C 1 0.28%
p.Arg1443His c. 4328 G>A 1 0.28%
p.Cys1490Tyr c.4469 G>A 54 14.92%
p.Gln1513Pro fs*42 c. 4535 insC 1 0.28%
p.Ala1598Asp c. 4793C>A 1 0.28%
p.Arg1640Trp c. 4918 C>T 2 0.55%
p.Ser1642Arg c. 4926 C>G 1 0.28%
p.V1681_C1685del c. 5041 del15 1 0.28%
- c. 5461–10T>C 24 6.63%
- c. 5714+5 G>A 2 0.55%
p.Pro1948Leu c. 5843 C>T 1 0.28%
p.Gly1961Glu c. 5882 G>A 4 1.10%
p.Leu2027Phe c.6079 C>T 30 8.29%
p.Arg2030* c. 6088 C>T 1 0.28%
p.Arg2030Gln c. 6089 G>A 3 0.83%
p.Arg2038Trp c. 6112 C>T 1 0.28%
p.Arg2107His c. 6320 G>A 2 0.55%
p.Arg2118Glu fs*27 c. 6352 delA 1 0.28%
p.Cys2150Tyr c. 6449 G>A 1 0.28%
p.Gln2220* c. 6658 C>T 1 0.28%
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286p.Gly863Ala mutation, which appears to have a founder effect
in  the  Netherlands  [13,15],  the  results  obtained  from  the
current  study  are  in  agreement  with  September  et  al.’s
conclusions [9].
Control  cohort  screening:  Previous  research  has
suggested the presence of founder mutations in the South
African  population  of  Caucasian  Afrikaner  descent.
Therefore, the Afrikaner-specific sub-cohort was of particular
interest in the current study. The results obtained from the
control cohort screening indicate that the carrier frequency of
the p.Cys1490Tyr, p.Arg602Trp, and p.Gly863Ala mutations
is  slightly  higher  compared  to  the  other  mutations
(p.Leu2027Phe, c.768G>T, and p.Arg152*), with the c.5461–
10T>C mutation not detected at all. The identification of
12/269  heterozygotes  in  the  control  cohort  reflected  a
background frequency of carriers in this population of 4.46
per 100 individuals (i.e., approximately 5% of South African
Caucasian individuals may be carriers of one of the seven
ABCA4  mutations  screened  in  the  present  study).  This  is
higher than other reports, estimating the carrier frequency to
be between 5% and 10% for all ABCA4 mutations (n>500)
tested for on the ABCR400 microarray [10]. When the control
cohort is subdivided, the observed carrier frequencies were
4% and 4.8% in the Caucasian and Afrikaner sub-cohorts,
respectively. However, as much as an emphasis was made to
recruit “Afrikaner” controls (n=169), the Caucasian control
cohort  (n=100)  was  not  selected  based  on  excluding  any
“Afrikaner”  ancestry,  and  the  findings  may  represent  an
unavoidable level of “admixture.” It is tempting to speculate
that  if  the  Caucasian  sub-cohort  had  consisted  only  of
individuals of British or English heritage, that an even higher
difference in frequency between the two subgroups might
have been observed. Despite this, the results obtained could
aid in genetic counseling when risk prediction is discussed
with patients and their family members.
Conclusion: The assays designed for this project used the
existence of seven common ABCA4 mutations in the South
African  population,  specifically  in  those  individuals  of
Afrikaner descent, and may be employed to target or direct
testing for research and diagnostic purposes. These assays will
potentially reduce costs to the research laboratory and patient.
The incorporation of the seven mutations into a single test
could be appealing in a diagnostic setting, where the test could
be  recommended  to  patients  by  counselors,  medical
geneticists, and ophthalmologists.
The carrier frequency of common ABCA4 mutations in
this particular population of Caucasian/Afrikaner descent was
indicated to be 4.46 per 100 individuals. This information can
be used to assist counselors in relating risk to patients and their
families during a genetic counseling session. Future work
regarding ABCA4 mutations could involve investigating the
frequencies  of  these  seven  mutations  in  other  population
groups, such as mixed ancestry and indigenous Black African,
for  comparison  with  the  frequencies  observed  in  the
Caucasian/Afrikaner population.
The molecular diagnosis of an AAR can be made only if
homozygous or compound heterozygous ABCA4 mutations
are identified in an individual. The ABCR400 microarray and
the other analysis methods presented here do not screen for
previously  uncharacterized  mutations.  Although  the  seven
mutations were found in a relatively large proportion of South
African patients screened, novel variants might also be found
to  be  diseasing-causing  in  a  significant  proportion  of
individuals affected with STGD. Therefore, carefully worded,
meaningful result reports must be delivered to patients by
counselors, as part of the ophthalmic genetic service offered
[22]. When mutations have not been proven to be biallelic (in
trans)  due  to  a  lack  of  samples  from  additional  family
members,  the  reports  state,  “Since  no  parental  DNA  was
available for verification, there is a possibility that two or all
of the mutations are on the same chromosome.” Furthermore,
the reports for patients screened for ABCA4 mutations state
that  “animal  studies  suggest  that  light  exposure  may
accelerate vision loss; wearing sunglasses in bright light or
sunshine may help protect vision; the investigators also agree
that  people  with  ABCA4-associated  RDDs  should  avoid
vitamin A supplementation” [23]. The molecular definition of
AARs  is  a  valuable  part  of  clinical  care  for  the  affected
families, as precautions that may limit disease progression
should be taken until treatment options become available.
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  Mutant alleles
Cohort p.Cys1490Tyr p.Arg602Trp p.Leu2027Phe       c.5461–10T>C c.768G>T p.Gly863Ala p.Arg152*
Patient (n=72; 144 alleles) 16 (11.11%) 10 (6.94%) 12 (8.33%) 13 (9.03%) 13 (9.03%) 7 (4.86%) 7 (4.86%)
Control (total; n=269; 538 alleles) 2 (0. 37%) 2 (0. 37%) 2 (0. 37%) 0 2 (0. 37%) 3 (0.56%) 1 (0.19%)
a) Caucasian (n=100; 200 alleles) 0 0 1 (0.5%) 0 1 (0.5%) 2 (1%) 0
b) Afrikaner (n=169; 338 alleles) 2 (0.59%) 2 (0.59%) 1 (0.296%) 0 1 (0.296%) 1 (0.296%) 1 (0.296%)
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On 6 August 2013, the following correction was made to Table 4, page 286. The numbering of the nucleotide change was 
corrected from "c.1885C>T" to "c.1804C>T".